Short answer
BIOCRYST PHARMACEUTICALS INC (BCRX) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $159M (up 36.1% year over year) with net income of $13M.
Q3 2025 key financials · XBRL
- Revenue
- $159M
- +36.1% YoY · −2.4% QoQ
- Net income
- $13M
- +191.9% YoY · +153.7% QoQ
- Operating margin
- 18.6%
- EPS (diluted)
- $0.06
- +185.7% YoY · +200.0% QoQ
Source: XBRL data from the BIOCRYST PHARMACEUTICALS INC (BCRX) Q3 2025 10-Q on SEC EDGAR. USD.
BIOCRYST PHARMACEUTICALS INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No new risk factors identified this quarter; risk disclosures unchanged from most recent 10-K
- Updated financial risk: uncertainty in sustaining profitability due to reliance on commercialization, competition, and achieving regulatory approvals
- Legal risk: obligations to pay royalties on ORLADEYO revenues under Royalty Purchase Agreements with RPI and OMERS detailed in financial notes
- Operational risk: ability to forecast capital allocation and execute commercialization plans impacts near-term financial performance
- Market risk: patient and physician acceptance, plus reimbursement levels, may adversely affect revenue projections
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other BIOCRYST PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.